Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo

BACKGROUND: Circulating levels of cancer antigen (CA) 15–3, a tumor marker and regulator of cellular metabolism, were reduced by metformin in a nonrandomized neoadjuvant study. We examined the effects of metformin (vs placebo) on CA 15–3 in participants of MA.32, a phase III randomized trial in earl...

Descripción completa

Detalles Bibliográficos
Autores principales: Goodwin, Pamela J, Dowling, Ryan J O, Ennis, Marguerite, Chen, Bingshu E, Parulekar, Wendy R, Shepherd, Lois E, Gelmon, Karen A, Whelan, Timothy J, Ligibel, Jennifer A, Hershman, Dawn L, Mayer, Ingrid A, Hobday, Timothy J, Rastogi, Priya, Rabaglio-Poretti, Manuela, Lemieux, Julie, Thompson, Alastair M, Rea, Daniel W, Stambolic, Vuk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410139/
https://www.ncbi.nlm.nih.gov/pubmed/34485814
http://dx.doi.org/10.1093/jncics/pkab066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410139/
https://www.ncbi.nlm.nih.gov/pubmed/34485814
http://dx.doi.org/10.1093/jncics/pkab066

Ejemplares similares